Sutter Neuroscience Medical Group
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kile, Shawn
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT06400368: Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Recruiting
N/A
200
US
NeuroVision Imaging
Mild Cognitive Impairment, Alzheimer Disease
04/26
04/26
Parise, Carol A
NCT04092647: Ashwagandha for Cognitive Dysfunction

Recruiting
2
80
US
Ashwagandha, Placebo
Sutter Health
Chemo Fog
12/24
07/25

Download Options